Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia.

The research article explores how Pentoxifylline, a drug, can inhibit the synthesis of inflammatory mediators in a lab-based blood model from horses experiencing endotoxemia. The study indicates that Pentoxifylline has the potential to be beneficial in the treatment of endotoxemia.

Research Methodology

• The researchers collected whole blood from 10 healthy horses in a sterile manner. The blood was put in either heparin or citrate anticoagulant.
• This blood was then incubated in vitro (in a controlled lab setting) for 6 hours, without any substances (saline control) or with 1 ng of endotoxin per ml of blood.
• Pentoxifylline was added to the blood either 1 hour before, simultaneously with, or 1 hour after the addition of endotoxin. The doses of Pentoxifylline varied: 0.1, 1, 10, or 100 micrograms per ml of blood.

Findings from the Study

• The study found that compared to the saline controls, Pentoxifylline had no impact on mediator production except for significantly increasing the concentration of 6-ketoprostaglandin F1 alpha.
• Pentoxifylline was able to inhibit the endotoxin-induced increases in tumor necrosis factor (TNF) and interleukin-6 (IL-6) activity, regardless of whether it was added before, with or after the endotoxin.
• Moreover, Pentoxifylline significanty inhibited tissue factor activity, but this effect was only observed when the drug was added before the endotoxin.
• Pentoxifylline, however, didn’t affect the production of 6-keto-prostaglandin F1 alpha induced by endotoxin. The drug was able to significantly inhibit the production of thromboxane B2 (TxB2).

Conclusions Drawn from the Research

• The collected data from this research suggest that Pentoxifylline inhibits the production of certain inflammatory mediators in a dose-related fashion in a lab-based blood model of infected horses.
• This action of Pentoxifylline is consistent with achievable concentrations in real-world, or in vivo, scenarios suggesting that the drug may offer beneficial effects in treating endotoxemia, a severe inflammatory condition.